$31.49
Today
as of Jul 22, 16:56 ET
Last 30 days
Recent Press Releases & News
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
Overview
52-week range
$8.91
$45
63% of range
Avg surprise (last 3)
+0.4%
Avg reaction (last 2)
+8.1%
100% positive
Latest IV / EM
84%
EM ±19.3% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-1.46 | $-1.37 | -6.6% | -82.5% | +4.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.22 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-1.25 | $-1.02 | -22.6% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.80 | $-1.15 | +30.4% | — | +12.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-5.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-24.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-17.89 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $1.96 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.89 | -$1.25 | +28.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $10M | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-77M | — | $-53M | $-55M | $-37M | — | $-41M | $-40M |
| Net income | $-81M | — | $-51M | $-52M | $-34M | — | $-39M | $-38M |
| EPS (diluted) | $-1.46 | — | $-1.22 | $-1.25 | $-0.80 | — | $-5.02 | $-24.23 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $500M | $111M | $116M | $44M | $197M | $320M | $360M | $184M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $730M | $351M | $297M | $279M | $318M | $356M | $394M | — |
| Total assets | $748M | $384M | $322M | $293M | $334M | $370M | $403M | — |
| Long-term debt | — | — | $73M | — | — | — | — | — |
| Total liabilities | $412M | $141M | $126M | $53M | $49M | $58M | $44M | — |
| Total equity | $336M | $242M | $196M | $240M | $284M | $312M | $359M | $-289M |